{"id":45477,"date":"2026-03-21T23:55:16","date_gmt":"2026-03-21T23:55:16","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/45477\/"},"modified":"2026-03-21T23:55:16","modified_gmt":"2026-03-21T23:55:16","slug":"novo-nordisk-shares-face-sustained-decline-analysis-and-outlook-news-and-statistics","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/45477\/","title":{"rendered":"Novo Nordisk Shares Face Sustained Decline: Analysis and Outlook &#8211; News and Statistics"},"content":{"rendered":"<p>\n\t\t\t\t\t\t\t\t\t\t\t\tMar 20, 2026\t\t\t\t\t<\/p>\n<p>Shares of Danish drugmaker <a href=\"https:\/\/app.indexbox.io\/companies\/profile\/721440\/\" target=\"_blank\" rel=\"noopener nofollow\">Novo Nordisk<\/a> have been in a full-blown tailspin over the past 12 months. The stock has lost more than half of its value as the company has been delivering some underwhelming results recently, and its guidance isnt looking too promising, either.<\/p>\n<p>Its been a bit of a perfect storm that has resulted in <a href=\"https:\/\/www.indexbox.io\/store\/branch\/pharmaceuticals_medicinal_chemical_and_botanical_products\/\" target=\"_blank\" rel=\"nofollow noopener\">Novo Nordisk<\/a> stock now tumbling to levels it hasnt been at since early 2021. Thats even before its weight loss drug, Wegovy, obtained approval from regulators, which was in the summer of that year.<\/p>\n<p>To say investors have been bearish on <a href=\"https:\/\/www.indexbox.io\/store\/denmark\/\" target=\"_blank\" rel=\"nofollow noopener\">Novo Nordisk<\/a> would be an understatement. But the big question is, has the bearishness become excessive , and has the healthcare stock become so cheap that its effectively become a no-brainer buy?<\/p>\n<p>Novo Nordisk may be down, but I wouldnt count it out<\/p>\n<p>Its a tough road ahead for Novo Nordisk as the company has a new CEO, and it slashed its guidance for the year ahead. It projects that its revenue could be down by as much as 13% for the current year, even as it has launched a new Wegovy pill.<\/p>\n<p>The company is facing pricing pressure, but management believes that by lowering prices, winning over customers, and gaining market share, it could set itself up for better growth in the future. Novo Nordisk has also reached a deal with telehealth company <a href=\"https:\/\/app.indexbox.io\/companies\/profile\/202859\/\" target=\"_blank\" rel=\"noopener nofollow\">Hims &amp; Hers Health<\/a> recently to sell its GLP-1 products on Hims platform, which could help grow sales even further. That announcement came after Novos troubling guidance, and thus, may result in better growth numbers than feared.<\/p>\n<p>The stock is a steal, even if youre concerned about its growth prospects<\/p>\n<p>The market has a tendency to overprice stocks that are doing well and undervalue ones that are struggling. But that can be good news for long-term investors, because it allows you to lock in a low price for a company that is underperforming. Billionaire investor Warren Buffett has said in the past that he likes to invest in businesses that are in &#8220;temporary trouble&#8221; simply because it can be highly advantageous to do so, particularly when the market is undervaluing them.<\/p>\n<p>In Novo Nordisks case, I think the business is facing temporary headwinds, and that its still a solid company to invest in for the long haul. The stock today trades just 10 times its earnings, which is a dirt cheap multiple for one of the top healthcare companies in the world. At this kind of valuation, youre getting an excellent margin of safety with the investment, and there could be significant upside in the future.<\/p>\n<p class=\"fs-5\">This report provides a comprehensive view of the prophylactic medicaments containing insulin industry in Denmark, tracking demand, supply, and trade flows across the national value chain. It explains how demand across key channels and end-use segments shapes consumption patterns, while also mapping the role of input availability, production efficiency, and regulatory standards on supply.<\/p>\n<p class=\"fs-5\">Beyond headline metrics, the study benchmarks prices, margins, and trade routes so you can see where value is created and how it moves between domestic suppliers and international partners. The analysis is designed to support strategic planning, market entry, portfolio prioritization, and risk management in the prophylactic medicaments containing insulin landscape in Denmark.<\/p>\n<p>Quick navigation<br \/>\nKey findings<\/p>\n<p>  Domestic demand is shaped by both household and industrial usage, with trade flows linking local supply to imports and exports.<br \/>\n  Pricing dynamics reflect unit values, freight costs, exchange rates, and regulatory shifts that affect sourcing decisions.<br \/>\n  Supply depends on input availability and production efficiency, creating a distinct national cost curve.<br \/>\n  Market concentration varies by segment, creating different competitive landscapes and entry barriers.<br \/>\n  The 2035 outlook highlights where capacity investment and demand growth are most aligned within the country.<br \/>\nReport scope<\/p>\n<p class=\"fs-5\">The report combines market sizing with trade intelligence and price analytics for Denmark. It covers both historical performance and the forward outlook to 2035, allowing you to compare cycles, structural shifts, and policy impacts.<\/p>\n<p>  Market size and growth in value and volume terms<br \/>\n  Consumption structure by end-use segments<br \/>\n  Production capacity, output, and cost dynamics<br \/>\n  Trade flows, exporters, importers, and balances<br \/>\n  Price benchmarks, unit values, and margin signals<br \/>\n  Competitive context and market entry conditions<br \/>\nProduct coverageProdcom 21201260 &#8211; Medicaments containing insulin but not antibiotics, for therapeutic or prophylactic uses, put up in measured doses or for retail saleCountry coverageCountry profile and benchmarks<\/p>\n<p class=\"fs-5\">This report provides a consistent view of market size, trade balance, prices, and per-capita indicators for Denmark. The profile highlights demand structure and trade position, enabling benchmarking against regional and global peers.<\/p>\n<p>Methodology<\/p>\n<p class=\"fs-5\">The analysis is built on a multi-source framework that combines official statistics, trade records, company disclosures, and expert validation. Data are standardized, reconciled, and cross-checked to ensure consistency across time series.<\/p>\n<p>  International trade data (exports, imports, and mirror statistics)<br \/>\n  National production and consumption statistics<br \/>\n  Company-level information from financial filings and public releases<br \/>\n  Price series and unit value benchmarks<br \/>\n  Analyst review, outlier checks, and time-series validation<\/p>\n<p class=\"fs-5\">All data are normalized to a common product definition and mapped to a consistent set of codes. This ensures that comparisons across time are aligned and actionable.<\/p>\n<p>Forecasts to 2035<\/p>\n<p class=\"fs-5\">The forecast horizon extends to 2035 and is based on a structured model that links prophylactic medicaments containing insulin demand and supply to macroeconomic indicators, trade patterns, and sector-specific drivers. The model captures both cyclical and structural factors and reflects known policy and technology shifts in Denmark.<\/p>\n<p>  Historical baseline: 2012-2025<br \/>\n  Forecast horizon: 2026-2035<br \/>\n  Scenario-based sensitivity to income growth, substitution, and regulation<br \/>\n  Capacity and investment outlook for major producing companies<\/p>\n<p class=\"fs-5\">Each projection is built from national historical patterns and the broader regional context, allowing the report to show where growth is concentrated and where risks are elevated.<\/p>\n<p>Price analysis and trade dynamics<\/p>\n<p class=\"fs-5\">Prices are analyzed in detail, including export and import unit values, regional spreads, and changes in trade costs. The report highlights how seasonality, freight rates, exchange rates, and supply disruptions influence pricing and margins.<\/p>\n<p>  Price benchmarks by country and sub-region<br \/>\n  Export and import unit value trends<br \/>\n  Seasonality and calendar effects in trade flows<br \/>\n  Price outlook to 2035 under baseline assumptions<br \/>\nProfiles of market participants<\/p>\n<p class=\"fs-5\">Key producers, exporters, and distributors are profiled with a focus on their operational scale, geographic footprint, product mix, and market positioning. This helps identify competitive pressure points, partnership opportunities, and routes to differentiation.<\/p>\n<p>  Business focus and production capabilities<br \/>\n  Geographic reach and distribution networks<br \/>\n  Cost structure and pricing strategy indicators<br \/>\n  Compliance, certification, and sustainability context<br \/>\nHow to use this report<\/p>\n<p>  Quantify domestic demand and identify the most attractive segments<br \/>\n  Evaluate export opportunities and prioritize target destinations<br \/>\n  Track price dynamics and protect margins<br \/>\n  Benchmark performance against leading competitors<br \/>\n  Build evidence-based forecasts for investment decisions<\/p>\n<p class=\"fs-5\">This report is designed for manufacturers, distributors, importers, wholesalers, investors, and advisors who need a clear, data-driven picture of prophylactic medicaments containing insulin dynamics in Denmark.<\/p>\n<p>FAQ<br \/>\nWhat is included in the prophylactic medicaments containing insulin market in Denmark?<\/p>\n<p class=\"fs-5\">The market size aggregates consumption and trade data, presented in both value and volume terms.<\/p>\n<p>How are the forecasts to 2035 built?<\/p>\n<p class=\"fs-5\">The projections combine historical trends with macroeconomic indicators, trade dynamics, and sector-specific drivers.<\/p>\n<p>Does the report cover prices and margins?<\/p>\n<p class=\"fs-5\">Yes, it includes export and import unit values, regional spreads, and a pricing outlook to 2035.<\/p>\n<p>Which benchmarks are included?<\/p>\n<p class=\"fs-5\">The report benchmarks market size, trade balance, prices, and per-capita indicators for Denmark.<\/p>\n<p>Can this report support market entry decisions?<\/p>\n<p class=\"fs-5\">Yes, it highlights demand hotspots, trade routes, pricing trends, and competitive context.<\/p>\n<p>\t\t1. INTRODUCTION<\/p>\n<p class=\"text-secondary fs-6\">Making Data-Driven Decisions to Grow Your Business<\/p>\n<p>\t\t\t\tREPORT DESCRIPTION<br \/>\n\t\t\t\tRESEARCH METHODOLOGY AND THE AI PLATFORM<br \/>\n\t\t\t\tDATA-DRIVEN DECISIONS FOR YOUR BUSINESS<br \/>\n\t\t\t\tGLOSSARY AND SPECIFIC TERMS<\/p>\n<p>\t\t2. EXECUTIVE SUMMARY<\/p>\n<p class=\"text-secondary fs-6\">A Quick Overview of Market Performance<\/p>\n<p>\t\t\t\tKEY FINDINGS<br \/>\n\t\t\t\tMARKET TRENDS<a class=\"px-2\" href=\"https:\/\/www.indexbox.io\/licenses\/\" target=\"_blank\" rel=\"nofollow noopener\">This Chapter is Available Only for the Professional Edition<\/a>PRO<\/p>\n<p>\t\t3. MARKET OVERVIEW<\/p>\n<p class=\"text-secondary fs-6\">Understanding the Current State of The Market and its Prospects<\/p>\n<p>\t\t\t\tMARKET SIZE: HISTORICAL DATA (2012\u20132025) AND FORECAST (2026\u20132035)<br \/>\n\t\t\t\tMARKET STRUCTURE: HISTORICAL DATA (2012\u20132025) AND FORECAST (2026\u20132035)<br \/>\n\t\t\t\tTRADE BALANCE: HISTORICAL DATA (2012\u20132025) AND FORECAST (2026\u20132035)<br \/>\n\t\t\t\tPER CAPITA CONSUMPTION: HISTORICAL DATA (2012\u20132025) AND FORECAST (2026\u20132035)<br \/>\n\t\t\t\tMARKET FORECAST TO 2035<\/p>\n<p>\t\t4. MOST PROMISING PRODUCTS FOR DIVERSIFICATION<\/p>\n<p class=\"text-secondary fs-6\">Finding New Products to Diversify Your Business<\/p>\n<p>\t\t\t\tTOP PRODUCTS TO DIVERSIFY YOUR BUSINESS<br \/>\n\t\t\t\tBEST-SELLING PRODUCTS<br \/>\n\t\t\t\tMOST CONSUMED PRODUCTS<br \/>\n\t\t\t\tMOST TRADED PRODUCTS<br \/>\n\t\t\t\tMOST PROFITABLE PRODUCTS FOR EXPORTS<\/p>\n<p>\t\t5. MOST PROMISING SUPPLYING COUNTRIES<\/p>\n<p class=\"text-secondary fs-6\">Choosing the Best Countries to Establish Your Sustainable Supply Chain<\/p>\n<p>\t\t\t\tTOP COUNTRIES TO SOURCE YOUR PRODUCT<br \/>\n\t\t\t\tTOP PRODUCING COUNTRIES<br \/>\n\t\t\t\tTOP EXPORTING COUNTRIES<br \/>\n\t\t\t\tLOW-COST EXPORTING COUNTRIES<\/p>\n<p>\t\t6. MOST PROMISING OVERSEAS MARKETS<\/p>\n<p class=\"text-secondary fs-6\">Choosing the Best Countries to Boost Your Export<\/p>\n<p>\t\t\t\tTOP OVERSEAS MARKETS FOR EXPORTING YOUR PRODUCT<br \/>\n\t\t\t\tTOP CONSUMING MARKETS<br \/>\n\t\t\t\tUNSATURATED MARKETS<br \/>\n\t\t\t\tTOP IMPORTING MARKETS<br \/>\n\t\t\t\tMOST PROFITABLE MARKETS<\/p>\n<p>\t\t7. PRODUCTION<\/p>\n<p class=\"text-secondary fs-6\">The Latest Trends and Insights into The Industry<\/p>\n<p>\t\t\t\tPRODUCTION VOLUME AND VALUE: HISTORICAL DATA (2012\u20132025) AND FORECAST (2026\u20132035)<\/p>\n<p>\t\t8. IMPORTS<\/p>\n<p class=\"text-secondary fs-6\">The Largest Import Supplying Countries<\/p>\n<p>\t\t\t\tIMPORTS: HISTORICAL DATA (2012\u20132025) AND FORECAST (2026\u20132035)<br \/>\n\t\t\t\tIMPORTS BY COUNTRY: HISTORICAL DATA (2012\u20132025)<br \/>\n\t\t\t\tIMPORT PRICES BY COUNTRY: HISTORICAL DATA (2012\u20132025)<\/p>\n<p>\t\t9. EXPORTS<\/p>\n<p class=\"text-secondary fs-6\">The Largest Destinations for Exports<\/p>\n<p>\t\t\t\tEXPORTS: HISTORICAL DATA (2012\u20132025) AND FORECAST (2026\u20132035)<br \/>\n\t\t\t\tEXPORTS BY COUNTRY: HISTORICAL DATA (2012\u20132025)<br \/>\n\t\t\t\tEXPORT PRICES BY COUNTRY: HISTORICAL DATA (2012\u20132025)<\/p>\n<p>\t\t10. PROFILES OF MAJOR PRODUCERS<\/p>\n<p class=\"text-secondary fs-6\">The Largest Producers on The Market and Their Profiles<\/p>\n<p>\t\tLIST OF TABLES<\/p>\n<p>\t\t\t\tKey Findings In 2025<br \/>\n\t\t\t\tMarket Volume, In Physical Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tMarket Value: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tPer Capita Consumption: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tImports, In Physical Terms, By Country, 2012\u20132025<br \/>\n\t\t\t\tImports, In Value Terms, By Country, 2012\u20132025<br \/>\n\t\t\t\tImport Prices, By Country, 2012\u20132025<br \/>\n\t\t\t\tExports, In Physical Terms, By Country, 2012\u20132025<br \/>\n\t\t\t\tExports, In Value Terms, By Country, 2012\u20132025<br \/>\n\t\t\t\tExport Prices, By Country, 2012\u20132025<\/p>\n<p>\t\tLIST OF FIGURES<\/p>\n<p>\t\t\t\tMarket Volume, In Physical Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tMarket Value: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tMarket Structure \u2013 Domestic Supply vs. Imports, in Physical Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tMarket Structure \u2013 Domestic Supply vs. Imports, in Value Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tTrade Balance, In Physical Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tTrade Balance, In Value Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tPer Capita Consumption: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tMarket Volume Forecast to 2035<br \/>\n\t\t\t\tMarket Value Forecast to 2035<br \/>\n\t\t\t\tMarket Size and Growth, By Product<br \/>\n\t\t\t\tAverage Per Capita Consumption, By Product<br \/>\n\t\t\t\tExports and Growth, By Product<br \/>\n\t\t\t\tExport Prices and Growth, By Product<br \/>\n\t\t\t\tProduction Volume and Growth<br \/>\n\t\t\t\tExports and Growth<br \/>\n\t\t\t\tExport Prices and Growth<br \/>\n\t\t\t\tMarket Size and Growth<br \/>\n\t\t\t\tPer Capita Consumption<br \/>\n\t\t\t\tImports and Growth<br \/>\n\t\t\t\tImport Prices<br \/>\n\t\t\t\tProduction, In Physical Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tProduction, In Value Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tImports, In Physical Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tImports, In Value Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tImports, In Physical Terms, By Country, 2025<br \/>\n\t\t\t\tImports, In Physical Terms, By Country, 2012\u20132025<br \/>\n\t\t\t\tImports, In Value Terms, By Country, 2012\u20132025<br \/>\n\t\t\t\tImport Prices, By Country, 2012\u20132025<br \/>\n\t\t\t\tExports, In Physical Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tExports, In Value Terms: Historical Data (2012\u20132025) and Forecast (2026\u20132035)<br \/>\n\t\t\t\tExports, In Physical Terms, By Country, 2025<br \/>\n\t\t\t\tExports, In Physical Terms, By Country, 2012\u20132025<br \/>\n\t\t\t\tExports, In Value Terms, By Country, 2012\u20132025<br \/>\n\t\t\t\tExport Prices, By Country, 2012\u20132025<\/p>\n","protected":false},"excerpt":{"rendered":"Mar 20, 2026 Shares of Danish drugmaker Novo Nordisk have been in a full-blown tailspin over the past&hellip;\n","protected":false},"author":2,"featured_media":45478,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[3335,20756,24640,25814,272,25815,25816,360,1910,3388],"class_list":["post-45477","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-glp-1","tag-hims-hers-health","tag-insulin","tag-levemir","tag-novo-nordisk","tag-novolog","tag-saxenda","tag-telehealth","tag-wegovy","tag-weight-loss-drug"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116269870231143303","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/45477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=45477"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/45477\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/45478"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=45477"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=45477"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=45477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}